Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI for progressing brain metastases in HER2-negative breast cancer
2024-514999-41-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in breast cancer, sponsored by MEDSIR. Primary endpoint: Intracranial objective response rate (ORR-IC) by modified RANO-BM with volumetric confirmation. Started Oct 2024; status: completed.
02
Drugs
irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514999-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514999-41-00.